Agency sees no need for restrictions after easing them two years ago:  The FDA is doing away with the Risk Evaluation and Mitigation Strategy (REMS) for the type 2 diabetes medication that contains rosiglitazone (Avandia).  The REMS was “no longer necessary to ensure that the benefits” of the drug outweigh its risks, the FDA announced on its website recently. The drug has been under scrutiny since 2007, when a meta-analysis found that rosiglitazone was linked to risk of myocardial infarction.